Company: PACB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001299130-25-000168
Chunk: 83

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
,915299,303271,631Basic net loss per share$(0.13)$(0.22)$(1.69)$(1.15)DilutedWeighted average shares used in computingdiluted net loss per share300,844272,915299,303271,631Diluted net loss per share$(0.13)$(0.22)$(1.69)$(1.15)The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Shares issuable upon conversion ofconvertible senior notes61,41531,06361,41531,063Equity awards42,59936,49642,59936,496See Note 7. Equity Plans and Share-Based Compensation for detailed information on equity awards.

NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATIONWe are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker ("CODM") is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.On a regular basis, our CODM reviews:•total revenues by category•total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation•net loss per shareOur assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.

Q3 Fiscal 2025 Form 10-Q25

A summary of the segment profit or loss, including significant segment expenses is as follows:Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Total revenue38,441 39,967 115,360 114,790 Less:Cost of revenue22,540 29,963 86,146 87,566 Research and development22,846 25,516 74,428 107,456 Sales and marketing15,465 18,435 55,057 64,779 General and administrative15,634 25